Idris Yakubu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Idris Yakubu has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Gaurav Gupta
Virginia Commonwealth University, Richmond, VA
8 shared publications - Dhiren Kumar
Virginia Commonwealth University
5 shared publications - Ryan J. Winstead
Department of Pharmacy, Virginia Commonwealth University Health, Richmond, VA 23298, USA
4 shared publications Andrew Brown
Department of Pharmacy, Virginia Commonwealth University Health System
3 shared publications- Chelsey Chenxi Song
Department of Pharmacy Virginia Commonwealth University Health System Richmond VA USA
3 shared publications Tracy Sparkes
Department of Pharmacy University of Maryland Medical Center Baltimore Maryland USA
3 shared publications
Latest Publications
- 18 December 2025
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 32 (6) , 890-900
Defining weight trajectory after liver transplantation using generative artificial intelligence
A better understanding of weight trajectories in liver transplant (LT) recipients is essential to improving clinical outcomes. We utilized Generative Artificial Intelligence (GenAI) to identify and visualize factors that exist but are not observable (latent factors or LF) that result from limitations in current knowledge or statistical approaches to model weight in LT recipients. Using GenAI, weight trajectories were modeled in 562 adult LT recipients with available weight data up to 36 months post-LT. Each weight trajectory was treated as an 8-dimensional vector (defined as time at LT to 3, 6, 9, …, 36 mo) to convert longitudinal weight data into cross-sectional data. Multivariate analyses were performed to determine the relationship between latent factors governing weight trajectories and clinical parameters. Two discernable patterns, or LF 1 and LF 2 , were identified from the GenAI model to incorporate individual patient trajectories that explained 99% of the weight after LT. Each patient’s weight trajectory, thus, represented the combination of the LF 1 and LF 2 . LF 1 , the dominant latent factor, demonstrated rapid weight flux early after transplant (2 was less prevalent and demonstrated 2 distinct trajectories: (A) initial weight gain in the first 12 months followed by weight loss and weight stabilization by 24–30 months, and (B) initial weight loss followed by rapid and continued weight gain after the first 12 months post-LT. In multivariate analysis, MASH cirrhosis and male gender were the strongest clinical predictors of future weight gain. Using a novel statistical approach (GenAI), we identified key weight gain trajectories in LT recipients to be incorporated into clinical practice for risk stratification and mitigation.
- 18 December 2025
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 32 (6) , 890-900
Defining weight trajectory after liver transplantation using generative artificial intelligence
A better understanding of weight trajectories in liver transplant (LT) recipients is essential to improving clinical outcomes. We utilized Generative Artificial Intelligence (GenAI) to identify and visualize factors that exist but are not observable (latent factors or LF) that result from limitations in current knowledge or statistical approaches to model weight in LT recipients. Using GenAI, weight trajectories were modeled in 562 adult LT recipients with available weight data up to 36 months post-LT. Each weight trajectory was treated as an 8-dimensional vector (defined as time at LT to 3, 6, 9, …, 36 mo) to convert longitudinal weight data into cross-sectional data. Multivariate analyses were performed to determine the relationship between latent factors governing weight trajectories and clinical parameters. Two discernable patterns, or LF 1 and LF 2 , were identified from the GenAI model to incorporate individual patient trajectories that explained 99% of the weight after LT. Each patient’s weight trajectory, thus, represented the combination of the LF 1 and LF 2 . LF 1 , the dominant latent factor, demonstrated rapid weight flux early after transplant (2 was less prevalent and demonstrated 2 distinct trajectories: (A) initial weight gain in the first 12 months followed by weight loss and weight stabilization by 24–30 months, and (B) initial weight loss followed by rapid and continued weight gain after the first 12 months post-LT. In multivariate analysis, MASH cirrhosis and male gender were the strongest clinical predictors of future weight gain. Using a novel statistical approach (GenAI), we identified key weight gain trajectories in LT recipients to be incorporated into clinical practice for risk stratification and mitigation.
- 30 January 2025
- Published by Wolters Kluwer Health in Current Opinion in Organ Transplantation
- Vol. 30 (2) , 96-102
Costimulation blockade: the next generation
Purpose of review: Calcineurin inhibitors (CNIs) are central to immunosuppression in kidney transplantation (KT), improving short-term outcomes but falling short in enhancing long-term outcomes due to cardiovascular, metabolic, and renal complications. Belatacept, an FDA-approved costimulation blocker, offers a less toxic alternative to CNIs but is limited by its intravenous administration and reduced efficacy in high-immunological-risk patients. Recent findings: Emerging therapies target more specific pathways to improve efficacy and accessibility. Abatacept, a first-generation cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) immunoglobulin, has shown favorable outcomes in small studies. VEL-101 and Lulizumab selectively block CD28 while preserving CTLA-4 signaling, showing promise in early trials. In the CD40/CD40L pathway, results have been mixed. Iscalimab (CD40 antibody) was inferior to tacrolimus in Phase 2 trials, and Bleselumab (CD40 antibody) showed variable rejection rates despite being noninferior to tacrolimus. CD40L-targeting agents such as TNX-1500, Tegoprubart, and Dazodalibep have demonstrated promising efficacy and safety in rejection prophylaxis. Summary: The focus in transplantation is shifting toward safer, long-term therapies with greater accessibility. Investigational agents with subcutaneous delivery methods could overcome logistical challenges, improve adherence, and redefine posttransplant care. These advancements in costimulation blockade may enhance long-term graft survival and transform the management of KT recipients.
- 30 January 2025
- Published by Wolters Kluwer Health in Current Opinion in Organ Transplantation
- Vol. 30 (2) , 96-102
Costimulation blockade: the next generation
Purpose of review: Calcineurin inhibitors (CNIs) are central to immunosuppression in kidney transplantation (KT), improving short-term outcomes but falling short in enhancing long-term outcomes due to cardiovascular, metabolic, and renal complications. Belatacept, an FDA-approved costimulation blocker, offers a less toxic alternative to CNIs but is limited by its intravenous administration and reduced efficacy in high-immunological-risk patients. Recent findings: Emerging therapies target more specific pathways to improve efficacy and accessibility. Abatacept, a first-generation cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) immunoglobulin, has shown favorable outcomes in small studies. VEL-101 and Lulizumab selectively block CD28 while preserving CTLA-4 signaling, showing promise in early trials. In the CD40/CD40L pathway, results have been mixed. Iscalimab (CD40 antibody) was inferior to tacrolimus in Phase 2 trials, and Bleselumab (CD40 antibody) showed variable rejection rates despite being noninferior to tacrolimus. CD40L-targeting agents such as TNX-1500, Tegoprubart, and Dazodalibep have demonstrated promising efficacy and safety in rejection prophylaxis. Summary: The focus in transplantation is shifting toward safer, long-term therapies with greater accessibility. Investigational agents with subcutaneous delivery methods could overcome logistical challenges, improve adherence, and redefine posttransplant care. These advancements in costimulation blockade may enhance long-term graft survival and transform the management of KT recipients.
- Open Access
- 5 October 2024
- Published by Wiley in Transplant Infectious Disease
- Vol. 26 (6) , e14387
Management of vancomycin‐resistant Enterococci and daptomycin‐resistant Enterococci infections in liver transplant recipients in a single academic center
Introduction: Vancomycin‐resistant Enterococci (VRE) infections cause significant morbidity and mortality in liver transplant (LT) recipients. Management is challenging, especially in the setting of daptomycin resistance (DR).Methods: Single‐center retrospective review of patients who underwent LT between January 1, 2020, and December 31, 2022, and developed VRE infections. Descriptive statistics were used and Kaplan‐Meier curves estimated freedom from treatment failure and survival.Results: Forty‐two patients (median age 58; 64% female; 67% white) were included. Alcohol‐related cirrhosis (48%) and metabolic dysfunction‐associated steatohepatitis (31%) were the most common indications for LT, and most were from deceased donors (86%). VRE infection occurred at a median of 21 days after LT, and 16% had known prior VRE colonization. Common infection sites were blood (45%, n = 19), intraabdominal (36%, n = 15), and urine (36%, n = 15). Most were initially treated with daptomycin alone (64%) or in combination with other agents (21%); 7% received linezolid alone. Twelve (29%) developed breakthrough infections during treatment and 11 (26%) had recurrent infections after discontinuation of treatment. All‐cause mortality was 36% (n = 15) at a median of 90 days after VRE infection diagnosis and was nearly twice as high in patients with DR (63%).Conclusion: VRE infection in LT recipients relapsed or recurred in over 25%. Mortality was high, especially in cases with DR. More data is needed to establish an optimal treatment approach, particularly for relapse and DR. image
- 5 October 2024
- Published by Wiley in Transplant Infectious Disease
- Vol. 26 (6) , e14387
Open AccessManagement of vancomycin‐resistant Enterococci and daptomycin‐resistant Enterococci infections in liver transplant recipients in a single academic center
Introduction: Vancomycin‐resistant Enterococci (VRE) infections cause significant morbidity and mortality in liver transplant (LT) recipients. Management is challenging, especially in the setting of daptomycin resistance (DR).Methods: Single‐center retrospective review of patients who underwent LT between January 1, 2020, and December 31, 2022, and developed VRE infections. Descriptive statistics were used and Kaplan‐Meier curves estimated freedom from treatment failure and survival.Results: Forty‐two patients (median age 58; 64% female; 67% white) were included. Alcohol‐related cirrhosis (48%) and metabolic dysfunction‐associated steatohepatitis (31%) were the most common indications for LT, and most were from deceased donors (86%). VRE infection occurred at a median of 21 days after LT, and 16% had known prior VRE colonization. Common infection sites were blood (45%, n = 19), intraabdominal (36%, n = 15), and urine (36%, n = 15). Most were initially treated with daptomycin alone (64%) or in combination with other agents (21%); 7% received linezolid alone. Twelve (29%) developed breakthrough infections during treatment and 11 (26%) had recurrent infections after discontinuation of treatment. All‐cause mortality was 36% (n = 15) at a median of 90 days after VRE infection diagnosis and was nearly twice as high in patients with DR (63%).Conclusion: VRE infection in LT recipients relapsed or recurred in over 25%. Mortality was high, especially in cases with DR. More data is needed to establish an optimal treatment approach, particularly for relapse and DR. image
- Open Access
- 12 December 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 24 (5) , 876-878
Ultrashort direct-acting antiviral prophylaxis for human immunodeficiency virus and hepatitis C virus coinfected donor positive to human immunodeficiency virus-positive kidney transplants
- 12 December 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 24 (5) , 876-878
Open AccessUltrashort direct-acting antiviral prophylaxis for human immunodeficiency virus and hepatitis C virus coinfected donor positive to human immunodeficiency virus-positive kidney transplants
- 4 July 2023
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 63 (6) , 1700-1705.e4
Cost minimization analysis of short-duration antiviral prophylaxis for hepatitis C positive donor kidney transplants
- 4 July 2023
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 63 (6) , 1700-1705.e4
Cost minimization analysis of short-duration antiviral prophylaxis for hepatitis C positive donor kidney transplants
- Open Access
- 24 March 2022
- Published by Wolters Kluwer Health in Transplantation
- Vol. 106 (4) , e234-e235
Ultrashort Duration Prophylaxis for Hepatitis C Donor Positive to Recipient Negative Simultaneous Kidney/Pancreas Transplants
- 24 March 2022
- Published by Wolters Kluwer Health in Transplantation
- Vol. 106 (4) , e234-e235
Open AccessUltrashort Duration Prophylaxis for Hepatitis C Donor Positive to Recipient Negative Simultaneous Kidney/Pancreas Transplants
- 26 August 2021
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 4 (11) , 1445-1456
Considerations and approaches to expansion of solid organ transplant pharmacist services
Solid organ transplantation is a lifesaving procedure for thousands of people with irreversible end organ diseases. A multidisciplinary approach with inclusion of a pharmacist in the care of transplant recipients is highly desired and may necessitate the addition of transplant pharmacy resources to existing teams to meet these growing needs. By understanding and leveraging the current landscape of leadership priorities, gathering the data to help define the value of pharmacy services, and compiling a formal proposal, one can systematically approach expansion of clinical pharmacy services. This manuscript seeks to provide a framework that can be utilized by pharmacy and transplant administrators, transplant pharmacists, and advocates for transplant pharmacy services for the purpose of evaluating, proposing, and successfully expanding the number of transplant pharmacist resources, including example job descriptions, return on investment examples, and key publications demonstrating the benefit of transplant and pharmacy services.
- 26 August 2021
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 4 (11) , 1445-1456
Considerations and approaches to expansion of solid organ transplant pharmacist services
Solid organ transplantation is a lifesaving procedure for thousands of people with irreversible end organ diseases. A multidisciplinary approach with inclusion of a pharmacist in the care of transplant recipients is highly desired and may necessitate the addition of transplant pharmacy resources to existing teams to meet these growing needs. By understanding and leveraging the current landscape of leadership priorities, gathering the data to help define the value of pharmacy services, and compiling a formal proposal, one can systematically approach expansion of clinical pharmacy services. This manuscript seeks to provide a framework that can be utilized by pharmacy and transplant administrators, transplant pharmacists, and advocates for transplant pharmacy services for the purpose of evaluating, proposing, and successfully expanding the number of transplant pharmacist resources, including example job descriptions, return on investment examples, and key publications demonstrating the benefit of transplant and pharmacy services.
- 28 June 2021
- Published by Wiley in Transplant Infectious Disease
- Vol. 23 (4) , e13678
Changes in cytomegalovirus‐specific T‐cell immunity with immunomodulation in serodiscordant high‐risk transplant recipients
Cytomegalovirus (CMV) infections can cause significant morbidity and mortality among serodiscordant (D+/R-) transplant recipients. CMV specific T cell immunity has been shown in previous studies to predict those at highest risk for CMV events. This is a retrospective study encompassing data on CMV discordant solid organ transplant recipients who received at least one CMV specific T cell immunity assay (CD4 and CD8) prior to cessation of universal prophylaxis. Our study demonstrated that patients with low CMV CD4/CD8 had improved CMV T cell immunity with changes to maintenance immunosuppression.
- 28 June 2021
- Published by Wiley in Transplant Infectious Disease
- Vol. 23 (4) , e13678
Changes in cytomegalovirus‐specific T‐cell immunity with immunomodulation in serodiscordant high‐risk transplant recipients
Cytomegalovirus (CMV) infections can cause significant morbidity and mortality among serodiscordant (D+/R-) transplant recipients. CMV specific T cell immunity has been shown in previous studies to predict those at highest risk for CMV events. This is a retrospective study encompassing data on CMV discordant solid organ transplant recipients who received at least one CMV specific T cell immunity assay (CD4 and CD8) prior to cessation of universal prophylaxis. Our study demonstrated that patients with low CMV CD4/CD8 had improved CMV T cell immunity with changes to maintenance immunosuppression.
- 20 January 2021
- Published by Wiley in Transplant Infectious Disease
- Vol. 23 (4) , e13570
Letermovir prophylaxis in solid organ transplant—Assessing CMV breakthrough and tacrolimus drug interaction
Background: Valganciclovir is the preferred drug for cytomegalovirus (CMV) prophylaxis in solid organ transplantation. A limitation to its use is profound myelosuppression. Letermovir is a new agent approved for CMV prophylaxis in hematopoietic stem cell transplantation and is associated with less toxicity. This study aims to assess the effectiveness and safety of letermovir in solid organ transplantation.Methods: A single‐center, matched cohort study was performed on 31 transplant recipients who were converted from valganciclovir to letermovir from November 2017 to June 2020. The primary outcome was the rate of CMV breakthrough infections while on prophylaxis. Secondary outcomes included rate of leukopenia, doses of immunosuppression, rejection, non‐CMV infection, and renal function. Statistical analyses of continuous variables included the student's t‐test, ANOVA test, and Wilcoxon Signed Rank test. Categorical data were analyzed with chi‐square test and Fisher’s Exact test.Results: There was no difference in the rate of CMV breakthrough between patients on letermovir (8.7%) and valganciclovir (13.5%), (P = .7097). After conversion to letermovir, patients required lower tacrolimus doses at ‐3.34 mg (SD‐1.3, P = .0273), between conversion and day 7. Transplant Infectious Disease The median difference in tacrolimus trough concentrations from conversion to day seven was 9.1 ng/ml [4.9, 16.95] (P = .0002). Leukopenia improved by 1.8 109/L [1.08, 4.85] (P < .0001).Conclusions: Patients converted from valganciclovir to letermovir did not show an increased rate of CMV breakthrough compared to a historical, matched cohort of patients remaining on valganciclovir. A significant drug interaction was noted with tacrolimus, leading to a recommendation to reduce the dose by 40‐50% upon initiation of letermovir.
- 20 January 2021
- Published by Wiley in Transplant Infectious Disease
- Vol. 23 (4) , e13570
Letermovir prophylaxis in solid organ transplant—Assessing CMV breakthrough and tacrolimus drug interaction
Background: Valganciclovir is the preferred drug for cytomegalovirus (CMV) prophylaxis in solid organ transplantation. A limitation to its use is profound myelosuppression. Letermovir is a new agent approved for CMV prophylaxis in hematopoietic stem cell transplantation and is associated with less toxicity. This study aims to assess the effectiveness and safety of letermovir in solid organ transplantation.Methods: A single‐center, matched cohort study was performed on 31 transplant recipients who were converted from valganciclovir to letermovir from November 2017 to June 2020. The primary outcome was the rate of CMV breakthrough infections while on prophylaxis. Secondary outcomes included rate of leukopenia, doses of immunosuppression, rejection, non‐CMV infection, and renal function. Statistical analyses of continuous variables included the student's t‐test, ANOVA test, and Wilcoxon Signed Rank test. Categorical data were analyzed with chi‐square test and Fisher’s Exact test.Results: There was no difference in the rate of CMV breakthrough between patients on letermovir (8.7%) and valganciclovir (13.5%), (P = .7097). After conversion to letermovir, patients required lower tacrolimus doses at ‐3.34 mg (SD‐1.3, P = .0273), between conversion and day 7. Transplant Infectious Disease The median difference in tacrolimus trough concentrations from conversion to day seven was 9.1 ng/ml [4.9, 16.95] (P = .0002). Leukopenia improved by 1.8 109/L [1.08, 4.85] (P < .0001).Conclusions: Patients converted from valganciclovir to letermovir did not show an increased rate of CMV breakthrough compared to a historical, matched cohort of patients remaining on valganciclovir. A significant drug interaction was noted with tacrolimus, leading to a recommendation to reduce the dose by 40‐50% upon initiation of letermovir.
- Open Access
- 13 September 2020
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 4 (2)
Early initiation of sodium‐glucose linked transporter inhibitors (SGLT‐2i) and associated metabolic and electrolyte outcomes in diabetic kidney transplant recipients
There is a paucity of data on the use of SGLT2 inhibitors on outcomes in kidney transplant recipients. There may be concern in initiating these agents, especially within the first year post‐transplant when renal function is more labile and immunosuppression more intense, due to a presumed high risk of urinary infections and acute kidney injury. This is a retrospective study on 50 kidney transplant recipients, half of whom were started on therapy within the first year of transplant. Over a follow‐up period of 6 months, overall patients had a statistically significant improvement in weight by −2.95 kg [SD 3.54, P = <.0001 (CI: 3.53, 1.50)] as well as hypomagnesemia 0.13 [SD 1.73, P = .0004 (CI: 0.06, 0.20)]. Overall insulin usage declined by −3.7 units [SD 22.8, P = .17]. 14% of patients had at least one urinary tract infection although this rate is not different (~20%) than that reported historically in this high‐risk population.
- 13 September 2020
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 4 (2)
Open AccessEarly initiation of sodium‐glucose linked transporter inhibitors (SGLT‐2i) and associated metabolic and electrolyte outcomes in diabetic kidney transplant recipients
There is a paucity of data on the use of SGLT2 inhibitors on outcomes in kidney transplant recipients. There may be concern in initiating these agents, especially within the first year post‐transplant when renal function is more labile and immunosuppression more intense, due to a presumed high risk of urinary infections and acute kidney injury. This is a retrospective study on 50 kidney transplant recipients, half of whom were started on therapy within the first year of transplant. Over a follow‐up period of 6 months, overall patients had a statistically significant improvement in weight by −2.95 kg [SD 3.54, P = <.0001 (CI: 3.53, 1.50)] as well as hypomagnesemia 0.13 [SD 1.73, P = .0004 (CI: 0.06, 0.20)]. Overall insulin usage declined by −3.7 units [SD 22.8, P = .17]. 14% of patients had at least one urinary tract infection although this rate is not different (~20%) than that reported historically in this high‐risk population.